Situation: A 24-year-old woman with asthma is brought to the emergency room (ER) with wheezing and breathlessness that began after a viral cold. At home she uses only a salbutamol (albuterol) inhaler, about 6 to 8 times a week. She has no other illness, takes no other medicines, and her oxygen saturation by pulse oximetry (SpO2) is monitored continuously. After she recovers, the physician prescribes a budesonide–formoterol inhaler to be used whenever she has symptoms. She says, "My cousin has a salmeterol–fluticasone inhaler, and her doctor told her never to use it for quick relief. Why can I use mine that way?" Which explanation should the nurse give?

Formoterol and salmeterol are both long-acting beta2 agonists, but formoterol has a fast onset, so an inhaler that combines it with an inhaled corticosteroid can relieve symptoms within minutes while treating inflammation with each use. Salmeterol has a slow onset and is not used as a reliever. The inhaled corticosteroid in either inhaler acts on inflammation over days, not minutes.

Core pharmacologic distinction
The patient is asking why a budesonide–formoterol inhaler can serve as an as-needed reliever while a salmeterol–fluticasone inhaler cannot. The answer rests on the difference between the two long-acting beta2-agonists (LABAs): formoterol and salmeterol.

Both formoterol and salmeterol are classified as LABAs because their bronchodilator effect lasts approximately 12 hours. However, their onset of action differs substantially. Formoterol begins to relax airway smooth muscle within 1–3 minutes of inhalation, comparable to the short-acting beta2-agonist salbutamol. Salmeterol, by contrast, has a slow onset of roughly 15–30 minutes or longer, which makes it unsuitable for acute symptom relief. ^[1]

Why the corticosteroid component does not explain rapid relief
The patient’s cousin was told never to use salmeterol–fluticasone for quick relief. A common misunderstanding is that the inhaled corticosteroid (ICS) in either combination might provide fast symptom improvement. It does not. Inhaled corticosteroids such as budesonide and fluticasone work on airway inflammation over days to weeks, not within minutes. Therefore, the rapid-relief property of budesonide–formoterol comes entirely from the formoterol component, not from budesonide.

Anti-inflammatory reliever (AIR) therapy concept
Current asthma guidelines have moved away from relying on short-acting beta2-agonist (SABA)-only rescue therapy. The rationale is that symptom worsening before an exacerbation involves both bronchoconstriction and airway inflammation. Using a SABA alone treats only bronchoconstriction while leaving inflammation unaddressed. ^[1]

Anti-inflammatory reliever (AIR) therapy combines an ICS with a fast-onset bronchodilator in a single inhaler used as needed for symptom relief. The two currently available AIR combinations are:

Combination	Bronchodilator onset	Role in AIR therapy
Budesonide–formoterol	Fast (1–3 min)	As-needed reliever and controller
ICS–salbutamol (albuterol)	Fast (3–5 min)	As-needed reliever and controller
Salmeterol–fluticasone	Slow (15–30 min)	Maintenance only, not for acute relief

The budesonide–formoterol combination is the most extensively studied AIR regimen, with randomized controlled trials demonstrating a substantial reduction in severe exacerbations when used as reliever therapy.

Why option 2 is correct and the others fail
Option 2 states that formoterol starts working within minutes while salmeterol works slowly. This directly addresses the pharmacologic basis for the different clinical roles of the two LABAs. ^[1]

Option 1 is incorrect because budesonide does not ease airway swelling within minutes; ICS effects on inflammation require days of regular use.

Option 3 is incorrect because it misclassifies formoterol as short-acting. Formoterol is a long-acting beta2-agonist with a fast onset; its duration of action is approximately 12 hours, which distinguishes it from salbutamol. ^[1]

Option 4 is incorrect because salmeterol can open the airways during an attack, but it does so too slowly to serve as a rescue medication. The issue is the speed of onset, not an absence of bronchodilator effect. ^[1]

Key point! The distinction between formoterol and salmeterol is not long-acting versus short-acting. Both are LABAs. The clinically meaningful difference is onset of action: formoterol is fast, salmeterol is slow. This single pharmacologic property determines whether a LABA-containing inhaler can be used as an as-needed reliever. ^[1]

Watch out! Do not equate the ICS component with rapid symptom relief. In both budesonide–formoterol and salmeterol–fluticasone, the corticosteroid addresses inflammation over days, not minutes. The fast relief in AIR therapy comes from the bronchodilator, not the steroid.

Clinical application for this patient
This patient used salbutamol 6–8 times per week, which indicates poor asthma control and overreliance on a SABA-only rescue strategy. Prescribing budesonide–formoterol as needed ensures that every reliever use also delivers an inhaled corticosteroid, addressing the underlying inflammation that contributes to symptom escalation. This approach is consistent with the anti-inflammatory reliever (AIR) strategy recommended in current guidelines to reduce severe exacerbation risk. ^[1]